4.8 Article

Cytomegalovirus: pathogen, paradigm, and puzzle

期刊

JOURNAL OF CLINICAL INVESTIGATION
卷 121, 期 5, 页码 1673-1680

出版社

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI45449

关键词

-

资金

  1. NIH [HL093294, HL102547, CA18029, AI26672]
  2. Roche Laboratories
  3. Vical Inc.
  4. Viropharma Inc.
  5. Chimerix Inc.

向作者/读者索取更多资源

Human cytomegalovirus (CMV), one of the eight herpesviruses that commonly infect humans, is best known for its propensity to cause disease in immunocompromised patients, especially transplant recipients, patients with advanced AIDS, and congenitally infected newborns. Advances in molecular virology coupled with improvements in diagnostic methods and treatment options have vastly improved our understanding of and ability to manage CMV, but many uncertainties remain, including the mechanisms of persistence and pathogenesis and its hypothesized roles in a variety of human illnesses. Here we review recent advances that are reshaping our view and approach to this fascinating virus.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据